Literature DB >> 3948112

Intracarotid BCNU leukoencephalopathy.

B K Kleinschmidt-DeMasters.   

Abstract

Intracarotid 1,3-bis(2-chloroethyl)-1-nitrosurea (BCNU) is now a frequently used chemotherapeutic agent for high-grade glial neoplasms. The toxicity from such therapy has not been well-documented. A 50-year-old man with a left frontoparietal grade 4 astrocytoma received three injections of intracarotid BCNU, 400 mg each, over a 2-month period. No radiation or other chemotherapy was ever given. He tolerated the BCNU injections well, with some reduction of tumor bulk, until the third dose. After his last injection, his condition gradually deteriorated; he became obtunded, and died 5 weeks later. At autopsy, the brain showed extensive cavitation and coagulative necrosis, fibrinoid vascular necrosis, edema, swollen axons, and bizarre cellular morphologic features confined to the BCNU perfusion territory. Grade 4 astrocytoma remained in the right hemisphere and in the left occipital lobe, sites outside the area of BCNU perfusion. Intracarotid BCNU can result in a severe leukoencephalopathy similar to that seen with methotrexate or delayed radionecrosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948112     DOI: 10.1002/1097-0142(19860401)57:7<1276::aid-cncr2820570703>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Treatment of malignant recurrent glioma by intra-arterial, infra-ophthalmic infusion of HECNU 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl) urea. A phase II study.

Authors:  M Poisson; J Chiras; F Fauchon; C Debussche; J Y Delattre
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

Review 2.  Treatments for astrocytic tumors in children: current and emerging strategies.

Authors:  Stanislaw R Burzynski
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  Assessing the autopsy.

Authors:  P N Nemetz; J Ludwig; L T Kurland
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

4.  Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions.

Authors:  S J Hassenbusch; J H Anderson; O M Colvin
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

5.  Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study.

Authors:  Daniel A Hamstra; Bradford A Moffat; Daniel E Hall; John M Young; Timothy J Desmond; Julie Carter; Dennis Pietronigro; Kirk A Frey; Alnawaz Rehemtulla; Brian D Ross
Journal:  J Neurooncol       Date:  2005-07       Impact factor: 4.130

6.  The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.

Authors:  H Brem; M G Ewend; S Piantadosi; J Greenhoot; P C Burger; M Sisti
Journal:  J Neurooncol       Date:  1995-11       Impact factor: 4.130

7.  In vivo measurement of tumor blood oxygenation by near-infrared spectroscopy: immediate effects of pentobarbital overdose or carmustine treatment.

Authors:  R G Steen; K Kitagishi; K Morgan
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma.

Authors:  B C Schem; O Dahl
Journal:  J Neurooncol       Date:  1991-06       Impact factor: 4.130

9.  Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.

Authors:  Michael D Jenkinson; Trevor S Smith; Brian Haylock; David Husband; Aditya Shenoy; Sobhan Vinjamuri; Carol Walker; Denis Pietronigro; Peter C Warnke
Journal:  J Neurooncol       Date:  2010-01-10       Impact factor: 4.130

10.  Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial.

Authors:  Samuel J Hassenbusch; Emilio M Nardone; Victor A Levin; Norman Leeds; Dennis Pietronigro
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.